| Assessment Status | Assessment process complete |
| HTA ID | 19039 |
| Drug | Liraglutide |
| Brand | Saxenda® |
| Indication | As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is, as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease. |
| Assessment Process | |
| Rapid review commissioned | 18/09/2019 |
| Rapid review completed | 24/10/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of liraglutide (Saxenda®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/10/2019 |
| Pre-submission consultation with Applicant | 12/11/2019 |
| Full submission received from Applicant | 08/06/2020 |
| Preliminary review sent to Applicant | 21/08/2020 |
| NCPE assessment re-commenced | 23/10/2020 |
| Follow-up to preliminary review sent to Applicant | 30/11/2020 |
| NCPE assessment re-commenced | 08/12/2020 |
| Factual accuracy sent to Applicant | 15/01/2021 |
| NCPE assessment re-commenced | 22/01/2021 |
| NCPE assessment completed | 09/02/2021 |
| NCPE assessment outcome | The NCPE recommends that liraglutide 3mg (Saxenda®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations January 2023.
